HRTX Heron Therapeutics Inc.

27.14
-0.93  -3%
Previous Close 28.07
Open 28.06
Price To Book 5.21
Market Cap 2117436501
Shares 78,019,031
Volume 1,131,192
Short Ratio
Av. Daily Volume 840,044

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date under priority review April 30, 2019.
HTX-011
Post operative pain
CRL Mar 28 2013. Approved August 10 2016.
APF530 - Sustol
Prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV)
Approval announced November 9, 2017.
CINVANTI (HTX-019)
Prevention of chemotherapy-induced nausea and vomiting (CINV)
Phase 2 data released June 21, 2018. Primary endpoint met.
HTX-011
Total knee arthroplasty

Latest News

  1. Heron Therapeutics (HRTX) Reports Q4 Loss, Tops Revenue Estimates
  2. Heron Therapeutics: 4Q Earnings Snapshot
  3. Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2018 and Recent Corporate Progress
  4. Heron Therapeutics to Present at the 8th Annual Leerink Partners Global Healthcare Conference
  5. How Much Did Heron Therapeutics, Inc.’s (NASDAQ:HRTX) CEO Pocket Last Year?
  6. Heron Therapeutics Announces Retirement of Robert Rosen as President
  7. Today's Research Reports on Trending Tickers: Mylan and Heron Therapeutics
  8. New Research Coverage Highlights Heron Therapeutics, IDACORP, Star Bulk Carriers, AngioDynamics, Marinus Pharmaceuticals, and Advaxis — Consolidated Revenues, Company Growth, and Expectations for 2019
  9. Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises
  10. 90% of Patients Remain Opioid-Free When HTX-011 Is Given with an Over-the-Counter Analgesic Regimen in New Multi-center Postoperative Pain Management Study
  11. Company News For Jan 2, 2019
  12. Heron Gains on Priority Review Designation for Pain Drug
  13. Heron Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
  14. Heron stock up 4.3% after opioid alternative granted priority review designation from FDA
  15. FDA Grants Priority Review Designation for Heron Therapeutics' NDA for HTX-011, a Non-Opioid for Postoperative Pain Management
  16. Hedge Funds Are Buying Heron Therapeutics Inc (HRTX)
  17. Today's Research Reports on Trending Tickers: Heron Therapeutics and Supernus Pharmaceuticals
  18. Report: Exploring Fundamental Drivers Behind Aclaris Therapeutics, Extreme Networks, Care, Air Lease, Globus Medical, and Heron Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments
  19. Today's Research Reports on Trending Tickers: Cronos Group and Heron Therapeutics
  20. When Will Heron Therapeutics Inc (NASDAQ:HRTX) Become Profitable?